Cadrenal Therapeutics, Inc. () Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

179.87 k

Shareholding (Jun 2025)

FII

0.08%

Held by 3 FIIs

DII

96.32%

Held by 4 DIIs

Promoter

0.00%

How big is Cadrenal Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Cadrenal Therapeutics, Inc. has a market capitalization of 25.82 million, with net sales of 0.00 million and a net profit of -12.84 million over the last four quarters. The company reported shareholder's funds of 7.44 million and total assets of 10.12 million as of Dec 24.

What does Cadrenal Therapeutics, Inc. do?

22-Jun-2025

Cadrenal Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $4 million and a market cap of $25.82 million. Key financial metrics include a negative P/E ratio, no dividend yield, and a return on equity of -174.24%.

Is Cadrenal Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 11, 2025, Cadrenal Therapeutics, Inc. shows a neutral trend with mixed indicators, including a mildly bullish weekly MACD and bearish KST, suggesting a lack of strong momentum.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 27 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.30

Return on Equity

-328.17%

Price to Book

6.37

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-4 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-13.75%

6 Months

-18.92%

1 Year

-20.77%

2 Years

48.0%

3 Years

0.0%

4 Years

0.0%

5 Years

0.0%

Cadrenal Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Is Cadrenal Therapeutics, Inc. technically bullish or bearish?

As of 11 September 2025, the technical trend for Cadrenal Therapeutics, Inc. has changed from mildly bearish to sideways. The current stance is neutral, with mixed indicators influencing the outlook. The weekly MACD is mildly bullish, while the daily moving averages indicate a mildly bearish trend. The Bollinger Bands are bullish on both weekly and monthly time frames, and the On-Balance Volume (OBV) is bullish as well. However, the KST is bearish on the weekly chart, and there are no signals from the RSI on either time frame. Overall, the mixed signals suggest a lack of strong momentum in either direction. Multi-period return data is not available for comparison with the S&P 500....

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

0.00%

EBIT Growth (5y)

-43.64%

EBIT to Interest (avg)

6.03

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.20

Sales to Capital Employed (avg)

-351.33

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

10.01%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

4.86

EV to EBIT

-2.04

EV to EBITDA

-2.04

EV to Capital Employed

-18.28

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-174.24%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

Bullish

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Jun 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 3 Schemes (3.61%)

Foreign Institutions

Held by 3 Foreign Institutions (0.08%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -54.17% vs -140.00% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.70",
          "val2": "-2.50",
          "chgp": "-48.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.70",
          "val2": "-2.40",
          "chgp": "-54.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -27.38% vs -25.37% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-11.00",
          "val2": "-7.60",
          "chgp": "-44.74%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-1.00",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-10.70",
          "val2": "-8.40",
          "chgp": "-27.38%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-3.70

-2.50

-48.00%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-3.70

-2.40

-54.17%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -54.17% vs -140.00% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-11.00

-7.60

-44.74%

Interest

0.00

Exceptional Items

0.00

-1.00

100.00%

Consolidate Net Profit

-10.70

-8.40

-27.38%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -27.38% vs -25.37% in Dec 2023

All Annual Results

Company CV

About Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Cadrenal Therapeutics, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Cadrenal Therapeutics, Inc.?

Watch in Real-Time

What does Cadrenal Therapeutics, Inc. do?

Is Cadrenal Therapeutics, Inc. technically bullish or bearish?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Is Cadrenal Therapeutics, Inc. technically bullish or bearish?

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Jun 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Cadrenal Therapeutics, Inc.

Company Coordinates